|Small: New progress in cell-based drug delivery for tumor treatment|
|Submission:张灿课题组 Date:2019-01-07 Page View:11|
Gastric cancer is one of the high mortality-rate cancers, and the life quality of patients is extremely poor for the limited benefit of standard chemoradiotherapy and accompanied toxicity. We exploited our cell-loading technology platform to deliver chemotherapy drugs, and made the latest progress in the treatment of gastric cancer. Albumin-bound paclitaxel (Abraxane) is currently a second-line chemotherapy for gastric cancer. It has better curative effect and lower toxicity than traditional paclitaxel. Our team loaded albumin-binding paclitaxel (Abraxane) into neutrophils, combined with moderate radiotherapy for tumor treatment in which radiotherapy releasing inflammatory factors drived drug-loaded neutrophils targeting the cancer lesions and released cytotoxic drug.
This work expands the technology platform and application of cell-loaded drugs, providing new opportunities for the treatment of advanced cancer. The research was recently published in Small (IF 9.598) "Neoadjuvant Chemotherapy Based on Abraxane / Human Neutrophils Cytopharmaceuticals with Radiotherapy for Gastric Cancer". Dr. Caoyun Ju was the first author and Professor Can Zhang was the Corresponding Author.